Is age limiting factor for nivolumab treatment?

05/2018

MUDr. Libor Havel

Pneumologická klinika, Thomayerova nemocnice, Praha

SUMMARY

Immunotherapy as a new treatment modality is currently widely accepted and perceived as a modality in NSCLC treatment, which is changing the prognosis of patients in the long term. But it is not entirely clear how immunotherapy is suitable for patients of advanced age.

KEY WORDS

immunotherapy, nivolumab, NSCLC, elderly patients